ABSTRACT
Objective: This study was initiated to assess procalcitoninas prognostic marker forcardiovascular complication in type2 diabetic patients
Subjects and methods: Forty type 2 diabetic patients without cardiovascular disease, forty type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in the present study. Serum procalcitoninlevels were assayed and correlated with metabolic parameters.ROC curve analysis was also done for this biochemical marker
Results: The mean level of procalcitonin was 707.17+/- 99.19ng/l in diabetic subjects versus 881.30+/- 123.56ng/l for the cardio-diabetic subjects [P < 0.0001]. Procalcitonin levels were significantly amplified in the cardio-diabetic patients with increasing C-reactive protein [CRP], triglycerides [TG], fasting blood glucose [FBG],and cholesterol [P = 0.004, 0.0005, 0.002 and 0.01 respectively]. From ROC curve analysis, it was observed that the area under curve for procalcitoninwas 0.878. This finding indicates the good validity of the above biomarker as aprognostic factor for cardiovascular complication in type 2 diabetic patients
Conclusion: This study evidences the usefulness of measuring serum levels of procalcitoninin diagnosis of cardiovascular complication in type 2 diabetic patients
ABSTRACT
Objective: The present study was aimed to assess chemerin as prognostic factor for cardiovascular complications in type2 diabetic patients
Patients and methods: Forty type 2 diabetic patients without cardiovascular disease, forty type 2 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in the present study. Chemerin levels were assayed and correlated with clinical pathological parameters. ROC curve analysis was also done for this biochemical marker
Results: The mean level of chemerin was 57.65+/- 15.69 ng/l in diabetic subjects versus 93.97 +/- 26.62 ng/l for the cardio-diabetic subjects [P < 0.0001].The chemerin levels were significantly elevated in the cardio-diabetic patients with increasing-reactive protein[CRP], triglycerides[TG], fasting blood glucose [FBG], glycated hemoglbin[HbA1C], micro-albumin and cholesterol [P < 0.0001, P < 0.0001, P = 0.005, P=0.04, P=0.011andP=0.0001 respectively]. From the ROC curve analysis, it was observed that the area under curve for chemerin was 0.877. This finding indicates the good validity of the above biomarker as a prognostic factor for cardiovascular complication in type 2 diabetic patients
Conclusion: It could be concluded that chemerin can be used as prognostic biomarker for cardiovascular complications in type 2 diabetic patients
ABSTRACT
The present study was conducted to evaluate the antiatherogenic effect of almond oil in diabetic rats. Forty five male white albino rats were divided into 3 groups: Control group, diabetic group and diabetic almond oil treated group. Experimental diabetes was induced by single subcutaneous injection of 50mg/kg body weight streptozotocin. After two months blood samples were collected, for assessment of triglycerides, total, HDL, and LDL cholesterol, insulin, intercellular adhesion molecule-1 (ICAM-1), nitrite and nitrate (NOx), hydrogen peroxide (H2O2), glutathione peroxidase activity (GPX) and DNA damage. Results showed that mean levels of cholesterol, triglyceride, LDL-cholesterol were significantly low and HDL-cholesterol was significantly high in diabetic group received almond oil compared to diabetic group. Mean concentrations of insulin, NOx , GPX activity were significantly high, and mean levels of H2O2 , ICAM-1, percent of DNA damage were significantly low in diabetic group received almond oil compared to diabetic group . The data confirmed property of almond oil as an antioxidant that ameliorates oxidative stress and revealed that it is efficiently improves endothelial function and protects against the development of atherosclerosis in STZ induced diabetic rats.
ABSTRACT
Impaired fibrinolysis increases the risk of cardiovascular diseases and favors the intravascular deposition of fibrin. Fibrinolysis is regulated through plasminogen activators, and especially inhibitors, primarily the plasminogen activator inhibitor-l [PAI-l]. First-degree relatives of type 2 diabetic subjects are supposed to be genetically prone to the development of clinical disease. It might be possible that hemostatic dysregulalion may be present even in normal glucose tolerant first-degree relatives. In the present study, we aimed to investigate the hemostatic parameters, including tissue plasminogen activator [tPA], fibrinogen, PAI-l antigen, and PAI-l activity, in a group of diabetic patients offspring in comparison with healthy control subjects who have no family history of diabetes. We also investigated relationships between these parameters and plasma insulin levels. We studied 40 nondiabetic offspring of type 2 diabetic population. There were 25 normoglycemic subjects without a family history of diabetes who served as the control group. Fasting and post-load insulin concentrations were significantly higher in the offspring group compared with those in the control group. Plasma fibrinogen and LPA antigen concentrations were comparable between offspring and control subjects. Plasma PAI-l antigen concentration was higher in offspring compared with control subjects. Similarly, plasma PAI-l activity was significantly higher in offspring compared with control subjects. Plasma PAI-l activity was positively correlated with plasma PAI-l antigen and fibrinogen concentrations. PAI-l activity also had an inverse correlation with HDL cholesterol concentration, and was significantly correlated with the Waist Hip Ratio [WHR], plasma fibrinogen, plasma tPA antigen, and HDL cholesterol. These data suggest that none obese normal glucose tolerant offspring of type 2 diabetic subjects have elevated PAI-l activity indicating to hypofibrinolysis. Despite the presence of hyperinsulinemia and, possibly, insulin resistance, there is no association between insulin levels and PAI-l activity in these subjects. Hypofibrinolysis associated with enhanced PAI-l activity may be a risk factor for early development of atherosclerosis in these subjects who are genetically prone to the development of diabetes in the future. Large-scale controlled studies are required to elucidate whether the increased prevalence of cardiovascular diseases present even at the diagnosis of overt diabetes is related to hypofibrinolysis, in the prediabetic state